Cefdinir Coverage for Streptococcus pneumoniae

Spectrum of Activity Against S. pneumoniae

Cefdinir's activity against S. pneumoniae is comparable to second-generation cephalosporins rather than other third-generation agents, which is a critical limitation 1, 2

Cefdinir covers approximately 98.4% of penicillin-susceptible S. pneumoniae (MIC <0.1 mg/mL) 3
Cefdinir covers approximately 49.2% of intermediately resistant strains (MIC 0.1-1.0 mg/mL) 3
Cefdinir covers only 0.5% of penicillin-resistant strains (MIC >2 mg/mL) 3

Amoxicillin or high-dose amoxicillin-clavulanate provides superior coverage (95.2% at high doses) and should be first-line 3, 4
Ceftriaxone or cefotaxime maintain >99% coverage even against intermediately resistant strains 5, 3
Respiratory fluoroquinolones (levofloxacin, moxifloxacin) provide >99% coverage across all resistance patterns 3, 6

Do not assume third-generation classification means superior pneumococcal coverage - cefdinir's activity is closer to second-generation agents 1, 2
Do not use cefdinir empirically in areas with high penicillin resistance (>25-35% in many U.S. regions as of guideline publication) 7, 6
Penicillin-resistant strains are often multiply resistant, limiting alternative oral options 5, 7

For empiric treatment of suspected S. pneumoniae infections, choose high-dose amoxicillin (4 g/day in adults, 90 mg/kg/day in children) or amoxicillin-clavulanate as first-line therapy 4
Reserve cefdinir for patients with non-type I penicillin allergies or when susceptibility testing confirms penicillin-susceptible strains 1
In regions with high resistance rates or for severe infections, use respiratory fluoroquinolones or parenteral ceftriaxone instead 5, 3

Amoxicillin remains the most active oral β-lactam against S. pneumoniae, and cefditoren and cefpodoxime are the most active oral cephalosporins, superior to cefdinir 8

Penicillin non-susceptible S. pneumoniae shows significant geographic variation in Europe, with rates ranging from <5% in northern European countries to >25% in southern and eastern Europe, such as Cyprus 43%, Malta 47%, Turkey 34%, and France 30% 8
The European Society of Clinical Microbiology and Infectious Diseases recommends considering the geographic resistance patterns when choosing an antibiotic for S. pneumoniae treatment 8

The prevalence of penicillin‑resistant S. pneumoniae varies markedly across Europe:

Cefdinir resistance arises primarily through three mechanisms (Clinical Microbiology and Infection, 2011):